Literature DB >> 6310001

Immunologic evidence of reinfection with varicella-zoster virus.

A M Arvin, C M Koropchak, A E Wittek.   

Abstract

Resistance to reinfection with varicella-zoster virus (VZV) was evaluated in immune adults who had household exposure to varicella. Sixty-four percent of 25 adults exposed to varicella had a fourfold or greater rise in IgG antibody to VZV or had a high initial IgG antibody titer to VZV that declined by fourfold. IgM antibody was detected in only 12% of 25 VZV-immune subjects. Seventy percent of 23 subjects exposed to varicella had IgA antibody to VZV compared with 13% of 23 subjects with antibody to VZV who had no recent exposure (P less than 0.001, chi 2 test). Enhanced cellular immunity was documented by an increase in lymphocyte transformation to VZV antigen from a mean +/- SE index of 7.8 +/- 1.30 to 15.3 +/- 2.56 (P = 0.01, paired t-test). The increase in immunity to VZV in many immune subjects exposed to VZV suggests the occurrence of subclinical reinfection.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6310001     DOI: 10.1093/infdis/148.2.200

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Phylogenetic analysis of varicella-zoster virus: evidence of intercontinental spread of genotypes and recombination.

Authors:  Winsome Barrett Muir; Richard Nichols; Judith Breuer
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

2.  The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster.

Authors:  G P Garnett; B T Grenfell
Journal:  Epidemiol Infect       Date:  1992-06       Impact factor: 2.451

3.  Antibody-capture enzyme-linked immunosorbent assays that use enzyme-labelled antigen for detection of virus-specific immunoglobulin M, A and G in patients with varicella or herpes zoster.

Authors:  A M van Loon; J T van der Logt; F W Heessen; M C Heeren; J Zoll
Journal:  Epidemiol Infect       Date:  1992-02       Impact factor: 2.451

4.  Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.

Authors:  Adriana Weinberg; Ann A Lazar; Gary O Zerbe; Anthony R Hayward; Ivan S F Chan; Rupert Vessey; Jeffrey L Silber; Rob R MacGregor; Kenny Chan; Anne A Gershon; Myron J Levin
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

5.  Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting?

Authors:  Joke Bilcke; Albert Jan van Hoek; Philippe Beutels
Journal:  Hum Vaccin Immunother       Date:  2013-01-15       Impact factor: 3.452

6.  The Epidemiology of Herpes Zoster After Varicella Immunization Under Different Biological Hypotheses: Perspectives From Mathematical Modeling.

Authors:  Giorgio Guzzetta; Piero Poletti; Stefano Merler; Piero Manfredi
Journal:  Am J Epidemiol       Date:  2016-03-18       Impact factor: 4.897

7.  Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping.

Authors:  Vladimir N Loparev; Antonio Gonzalez; Marlene Deleon-Carnes; Graham Tipples; Helmut Fickenscher; Einar G Torfason; D Scott Schmid
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

8.  Varicella susceptibility in a Canadian population.

Authors:  S Ratnam
Journal:  Can J Infect Dis       Date:  2000-09

9.  Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians.

Authors:  Benson Ogunjimi; Evelien Smits; Steven Heynderickx; Johan Van den Bergh; Joke Bilcke; Hilde Jansens; Ronald Malfait; Jose Ramet; Holden T Maecker; Nathalie Cools; Philippe Beutels; Pierre Van Damme
Journal:  Clin Vaccine Immunol       Date:  2014-01-15

Review 10.  Varicella zoster virus infection.

Authors:  Anne A Gershon; Judith Breuer; Jeffrey I Cohen; Randall J Cohrs; Michael D Gershon; Don Gilden; Charles Grose; Sophie Hambleton; Peter G E Kennedy; Michael N Oxman; Jane F Seward; Koichi Yamanishi
Journal:  Nat Rev Dis Primers       Date:  2015-07-02       Impact factor: 52.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.